In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

Lipoprotein Apheresis: a New Approach to Refractory Angina?

Prevention


Rome, Italy – 29 August, 2016:

Lipoprotein apheresis, a therapy normally used to filter excess cholesterol from the blood of patients with familial hypercholesterolemia, may have a new role in patients with refractory angina.

New results reported during a Hot Line session at ESC Congress 2016 showed the extracorporeal treatment resulted in significant improvements compared to sham therapy in patients who had refractory angina along with raised levels of lipoprotein(a).

“Angina which is refractory to both medical therapy and revascularisation is a debilitating condition that is increasing in frequency, and there is a pressing need for novel treatments for these patients,” said lead investigator Tina Khan, MRCP, from Royal Brompton and Harefield NHS Trust and Imperial College in London, United Kingdom.

The apheresis procedure study was conducted at Harefield Hospital, under the Directorship of the Principal Investigators Mahmoud Barbir, FRCP and Dudley Pennell, MD.

“These patients continue to suffer with troublesome angina despite optimal medical therapy, as well as surgical and/or percutaneous coronary revascularization, and available treatment options are limited,” she added.

“Our trial provides the first evidence that lipoprotein apheresis leads to improvement among these patients in the primary endpoint of myocardial blood flow, as measured by myocardial perfusion reserve, as well as the secondary endpoints of exercise capacity, angina symptoms, quality of life and atheroma burden. Therefore this treatment approach could improve the cardiac health and lives of such patients.”

Lipoprotein(a) - abbreviated as Lp(a) - is similar in structure to LDL cholesterol, except for an additional protein attached called apolipoprotein(a). Raised Lp(a) is a strong risk factor for coronary heart disease and may be prevalent in patients with refractory angina.

Studies suggest that elevated Lp(a) may promote atherosclerosis and reduce blood flow through the heart (myocardial perfusion), but there is currently no effective pharmacologic treatment yet approved to treat elevated Lp(a) - and it is essentially resistant to conventional lipid-lowering treatment with statins, said Dr. Khan.

However, Lp(a) can effectively lowered with lipoprotein apheresis.

The prospective randomised, sham controlled, blinded, cross-over study included 20 patients with refractory angina and elevated Lp(a) levels above 500mg/L.

Participants were randomised to weekly lipoprotein apheresis or sham treatments for 3 months and then crossed over for another 3 months, with a one-month washout period in-between.

The primary outcome, measured with cardiac magnetic resonance imaging, was Myocardial Perfusion Reserve (MPR) – which is the ratio of the myocardial blood flow at stress versus rest after three months of lipoprotein apheresis, compared to baseline.

The study showed a significant increase of 0.63 in MPR after apheresis treatment compared to sham (P<0.001). Specifically, MPR increased from 1.45 to 1.93 with apheresis, but did not change significantly after sham.

Secondary endpoints of carotid wall volume and distensibility were also improved after apheresis but not sham, as were exercise capacity, symptoms of angina, and quality of life scores, said Dr. Khan.

In terms of symptoms, there were significant improvements after apheresis but not sham in 4 out of 5 domains in the Seattle Angina Questionnaire (SAQ), including the:

*Physical limitation score (median change of 27.8 vs -4.2);

*Angina stability score (mean change of 17.5 vs -3.75);

*Angina frequency score (mean change of 35.0 vs -5.0);

*Quality of life score (mean change of 25.8 vs 4.6).  

On the fifth domain, SAQ treatment satisfaction score improved slightly by 6.25 during apheresis vs 0.0 or no change during sham.

Similarly, physical component scores of quality of life assessed by the Short Form (SF)-36 Questionnaire also improved significantly after apheresis but not sham.

“Our study is the first randomised controlled trial to assess the impact of lipoprotein apheresis in patients with refractory angina and raised Lp(a), in the absence of significantly raised LDL cholesterol,” said Dr. Khan.

“These findings suggest that lipoprotein apheresis provides significant clinical benefit to patients with refractory angina in the context of raised Lp(a), representing a much needed novel treatment option for this therapeutically challenging patient cohort.”

Notes to editor

Sources of funding: Funded by the National Institute for Health Research Cardiovascular Biomedical Research Unit at Royal Brompton and Harefield Hospital NHS Foundation Trust and Imperial College London. Apheresis equipment used in the trial was provided by Kaneka Pharma Europe and LINC Medical.

Disclosures: Dr. Khan has no relevant disclosures. Prof. Pennell is a consultant to Siemens and Bayer, and a stockholder and director of Cardiovascular Imaging Solutions, and another investigator is a Siemens employee.

For press enquiries, please contact, the Media & Press Coordinator, Jacques Olivier Costa: +393427028575 

For independent comment on site, please contact the ESC Spokesperson coordinator, Celine Colas: +393402405148 

To access all the scientific resources from the sessions during the congress, visit ESC Congress 365.  

About the European Society of Cardiology
The European Society of Cardiology brings together health care professionals from more than 120 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

About ESC Congress 2016

ESC Congress is the world’s largest gathering of cardiovascular professionals contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2016 takes place 27 to 31 August at the Fiera di Roma in Rome, Italy. The scientific programme is here. More information is available from the ESC Press Office at press@escardio.org

 

The press conference timetable is available here. 

Information on Hot Line sessions available here.

To access all the scientific resources from the sessions during the congress, visit ESC Congress 365.  

This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2016. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.